Dysphagia in Lewy Body Dementia: Managing Fluctuating Swallowing Safety

Lewy body dementia (LBD) — encompassing dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) — is the second most common form of degenerative dementia after Alzheimer’s disease, affecting approximately 10–15% of all dementia cases. Its dysphagia is distinctive and presents unique management challenges: swallowing function in LBD is not static but fluctuates in parallel with the characteristic cognitive fluctuations that define the condition.

This article follows ASHA Practice Portal guidance on adult dysphagia and NICE CG162.

Pathophysiology of Dysphagia in LBD

LBD is caused by alpha-synuclein protein aggregation (Lewy bodies and Lewy neurites) in cortical neurons, Parkinson’s-related midbrain nuclei, and the autonomic nervous system. This produces a characteristic triad:

Parkinsonism — hypokinesia, rigidity and bradyphrenia affecting oral and pharyngeal motor function
Visual hallucinations and cognitive fluctuations — episodic, unpredictable reductions in consciousness and attention affecting voluntary oral phase control
Autonomic dysfunction — including reduced cough reflex sensitivity and oropharyngeal hypomotility

The dysphagia in LBD therefore combines elements of both Parkinson’s disease dysphagia (dopamine-deficient motor impairment) and dementia-related dysphagia (impaired voluntary oral sequencing and reduced mealtime attention).

Cognitive Fluctuations and Swallowing Safety

The defining clinical challenge in LBD dysphagia is that swallowing safety varies day to day — and sometimes hour to hour. During lucid periods, a patient may swallow IDDSI Level 7 (Regular) foods with adequate safety. During fluctuant periods — when the patient appears confused, drowsy, or hypoactive — the same patient may silently aspirate on thin liquids.

This fluctuation creates a dilemma:

Setting the IDDSI level based on the worst observed state may over-restrict diet unnecessarily during good periods
Setting it based on the best state risks aspiration during fluctuant periods

Current best practice guidance suggests:

Instrumental assessment during both a lucid and a fluctuant period if possible — VFSS or FEES conducted when the patient is in a typical fluctuant state, not just their best day
Caregiver training to recognise fluctuation signs and modify the feeding approach accordingly (e.g., switch to Level 2 liquid thickening during drowsy periods)
Documentation of fluctuation patterns to identify predictable times of day when risk is highest

Hallucinations and Mealtime Distress

Visual and auditory hallucinations during meals are common in LBD and can profoundly disrupt safe eating:

Patients may refuse to eat food they believe is contaminated or threatening
Startled responses during swallowing can precipitate aspiration
Attending to hallucinations reduces attention to voluntary oral phase control

Management strategies include:

Minimising environmental stimulation during meals (quiet room, reduced visual complexity)
Carer reassurance and distraction techniques
Review of medications that may worsen hallucinations (see below)

Medication Considerations

Neuroleptic sensitivity is a hallmark feature of LBD and is critical for the swallowing clinician to understand. Conventional antipsychotics (haloperidol, chlorpromazine) and even some atypical antipsychotics can cause life-threatening neuroleptic sensitivity reactions in LBD, producing severe Parkinsonism, reduced consciousness and dramatically worsened dysphagia. Even low doses have produced fatalities in LBD.

This means that behavioural approaches must be prioritised for managing hallucinations and mealtime distress before any pharmacological option is considered. If medication is necessary, liaison with a neurologist experienced in LBD is essential before prescription.

Cholinesterase inhibitors (rivastigmine, donepezil) are recommended for cognitive symptoms in LBD and may improve lucidity, attention and therefore mealtime safety. However, their effect on swallowing function specifically has not been rigorously studied.

Levodopa may improve the Parkinsonian motor component of LBD dysphagia during “on” periods, as in Parkinson’s disease.

IDDSI Management

The IDDSI framework provides the structure for safe texture and liquid modification in LBD, with the important caveat that single assessment snapshots may underestimate the need for modification during fluctuant periods. A pragmatic approach:

Use VFSS or FEES findings from a fluctuant or typical (not best-case) assessment to set the minimum IDDSI level
Prescribe for the worst reasonable state rather than the best
Include a plan for escalating precautions (e.g., switching to IDDSI Level 3 liquids, providing caregiver-supervised meals only) when fluctuation is observed

LBD patients may also need mixed consistency management: if their lucid state permits regular food but their fluctuant state requires Level 4 (Puréed), caregivers need clear, written guidance on when to apply each level.

Hong Kong Context

In Hong Kong, LBD is often underdiagnosed relative to Alzheimer’s disease, partly because cognitive fluctuations may be attributed to delirium or medication effects. Caregivers in residential care homes may not be trained to recognise LBD-specific dysphagia patterns. The HKU Swallowing Research Lab (Prof. Karen Chan) has highlighted the need for condition-specific SLT training in LBD, rather than applying generic dementia dysphagia protocols that do not account for motor fluctuations.

For referral guidance, see When to Refer to a Speech and Language Therapist.

References

American Speech-Language-Hearing Association. Adult Dysphagia Practice Portal. https://www.asha.org/practice-portal/clinical-topics/adult-dysphagia/
National Institute for Health and Care Excellence. Stroke Rehabilitation in Adults (CG162). https://www.nice.org.uk/guidance/cg162
IDDSI. The IDDSI Framework. https://www.iddsi.org/framework
Logemann JA, et al. (2015). Disorders of deglutition. Handbook of Clinical Neurology, 129, 465–487. PMID: 26315994